Oncolines proudly announces its contribution alongside the Institute of Research in Biomedicine (IRB) and OM Pharma in shedding light on the intricate workings of OM-85, commonly known as Broncho-Vaxom®.
Oncolines contributes to publication in Nature Communications
Oncolines contributes to publication in Nature Communications. Identification of first-in-class, potent and selective CK1α degrader.
Oncolines publishes with Elevar Therapeutics on selective VEGFR2 inhibitor rivoceranib
Vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of tumor angiogenesis, the formation of new blood vessels from existing vasculature. VEGFR2 has been an attractive target for anti-cancer therapy. The study highlights the power of combining Oncolines’ ResidenceTimer platform and Carna Bioscience’s kinase activity profiling.
New Oncolines publication in Cancers
In a recent paper published in Cancers, Yvonne Grobben from Oncolines investigated the role of various immunosuppressive amino acid-metabolizing enzymes in high-grade serous ovarian cancer.
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities
Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), announces the acquisition of Oncolines, a Netherlands-based CRO that provides early biology services and cell-line profiling assays. Oncolines is Symeres’ third acquisition in the past ten months, and will take group revenues to over €100m.
10 years Pivot Park: Oncolines
“Oncolines is a subsidiary of the Netherlands Translational Research Center (NTRC), the company I started in 2012 with my MSD/Organon colleague Rogier Buijsman,” says Zaman. “From 2012 to 2021, NTRC worked on new technologies to help develop novel drug candidates. These include a cancer cell line panel and bioinformatics analysis tools. We used these technologies to support our in-house drug discovery but also to provide services for clients. Over the years, NTRC has developed so fast that we decided to separate the precision medicine services and to expand it further as Oncolines.”
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from aberrant proliferation of T cell progenitors and accounts for 15% of pediatric ALL cases. Current standard treatment, consisting of high-dose multiagent chemotherapy, has led to an overall survival rate exceeding 80%. Nevertheless, one out of five children with T-ALL will relapse within four years after the start of therapy. New treatment options are urgently needed.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.